Trial Profile
The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Taxanes (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms REVER
- 27 Jan 2022 Status changed from recruiting to discontinued.
- 01 Sep 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
- 01 Sep 2020 Planned primary completion date changed from 1 Nov 2020 to 1 Nov 2022.